Hashemipour Mahin, Ghasemi Mahmoud, Hovsepian Silva, Heiydari Kamal, Sajadi Ali, Hadian Rezvaneh, Mansourian Marjan, Mirshahzadeh Naghme, Kelishadi Roya, Dalvi Marzie
Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran ; Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2014 Jan 9;3:21. doi: 10.4103/2277-9175.124658. eCollection 2014.
Considering the higher prevalence of congenital hypothyroidism (CH) in Iran and the importance of determination of the etiology of CH for assessing appropriate treatment strategies, understanding the pathogenesis of CH and the implications of its inheritance and prognosis, the aim of this study was to determine the etiology of CH 7 years after initiation of the program in Isfahan province.
In this cross-sectional study, children with a primary diagnosis of CH studied. They clinically examined and their medical files were reviewed by a Pediatric Endocrinologist. Considering screening and follow-up lab data and radiologic findings the etiology of CH was determined. Screening properties of different etiologies of CH was compared.
In this study, 437 patients with permanent CH (PCH) were studied. Etiology of PCH in 316 (72.3%) and 121 (27.7%) of cases was thyroid dyshormonogenesis and thyroid dysgenesis, respectively. Prevalence of agenesis, ectopia, hypoplasia and hemiagenesis in thyroid dysgenetic patients was 13.3%, 6.4%, 4.3% and 3.7% respectively. Mean of thyroid stimulating hormone in screening, recall and after discontinuing treatment at 3 years of age was significantly lower in dyshormonogenetic CH patients than dysgenetic ones(P < 0.01).
Seven years of our experiences in CH screening program indicated that the etiology of CH in Isfahan, with a higher rate of CH, with a predominance of thyroid dyshormonogenesis is different from most of the studies world-wide and similar to other reports from Iran. The findings of the current study provide us baseline information for determination of CH pathogenesis in this region.
鉴于伊朗先天性甲状腺功能减退症(CH)的患病率较高,且确定CH的病因对于评估适当的治疗策略、理解CH的发病机制及其遗传和预后的意义十分重要,本研究的目的是确定在伊斯法罕省启动该项目7年后CH的病因。
在这项横断面研究中,对初步诊断为CH的儿童进行了研究。由儿科内分泌学家对他们进行临床检查并查阅其病历。根据筛查和随访实验室数据以及影像学检查结果确定CH的病因。比较了CH不同病因的筛查特性。
在本研究中,对437例永久性CH(PCH)患者进行了研究。PCH的病因在316例(72.3%)和121例(27.7%)病例中分别为甲状腺激素合成障碍和甲状腺发育异常。甲状腺发育异常患者中无甲状腺、异位甲状腺、甲状腺发育不全和半侧无甲状腺的患病率分别为13.3%、6.4%、4.3%和3.7%。甲状腺激素合成障碍性CH患者在筛查、召回及3岁停药后的促甲状腺激素平均值显著低于甲状腺发育异常患者(P<0.01)。
我们在CH筛查项目中的7年经验表明,伊斯法罕CH的病因与世界上大多数研究不同,CH发病率较高,以甲状腺激素合成障碍为主,与伊朗的其他报告相似。本研究结果为确定该地区CH的发病机制提供了基线信息。